首个治疗癌症恶病质的新药阿那莫林已上市,效果怎么样？

Anamorelin is a new drug for the treatment of cancer cachexia. It has been launched in Japan. The drug has the effect of increasing body weight, muscle mass, and appetite, and helps improve the quality of life of patients with cancer cachexia. It is produced and developed by Ono Pharmaceutical. Today we will learn about the therapeutic effect of this drug?

Anamorelin is a new oral drug and the first drug to treat cancer cachexia. Patients with advanced cancer often suffer from cachexia, which is manifested by weight loss and anorexia. Patients with pancreatic cancer, non-small cell lung cancer, gastric cancer, colorectal cancer and other malignant tumors can use this drug to treat cachexia. So, what about it?

A total of 174 patients with cachectic, inoperable, stage III or IV non-small cell lung cancer (NSCLC) were included in the trial. After 12 weeks of treatment with anamorelin and placebo, the results showed that the LBM of patients in the anamorelin group increased by 1.38±0.18 kg. At 3 and 9 weeks of treatment, anamorelin increased prealbumin levels. In the placebo group, LBM decreased by 0.17±0.17 kg. NSCLC patients tolerated anamorelin treatment well. It increased lean body mass and improved anorexia symptoms in patients with advanced non-small cell lung cancer.

Anamorelin, a selective ghrelin receptor agonist, marks an important milestone in improving the quality of life of all patients with cancer cachexia as the first drug to treat cancer cachexia. The drug is easy to use, 100 mg each time, and can be taken orally once a day on an empty stomach. Pay attention to your own reactions during the medication, but do not use it on patients who have difficulty in oral intake or poor digestion and absorption of food. Patients should take it on time and in the right amount, so that the drug can achieve the best therapeutic effect.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: